Answers are grounded in this paper and cite their sources.
Abstract Background Nivolumab monotherapy is the standard second-line treatment for advanced esophageal squamous cell carcinoma (ESCC) after failure of platinum-based chemotherapy without anti-PD-1 antibody. Fixed dosing with 240 mg every 2 weeks was approved initially, followed by fixed dosing with 480 mg every 4 weeks based on pharmacokinetics data. However, information on the comparative efficacy and safety of the two doses remains limited. Methods We compared progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and the incidence of adverse events (AEs) between the two doses in 117 patients who received second-line(n=85) or later-line(n=32) nivolumab monotherapy at our institution between January 2016 and December 2021. Results Patient characteristics in the second-line group were as follows (240 mg vs. 480 mg): performance status (PS) 0/1/2, 34/61/5% vs 54/42/4%; prior FP, 81.3 vs. 42.3%. Those in the later-line group were as follows: PS 0/1/2, 28/60/12% vs. 14/86/0%; prior FP, 60.0 vs. 42.8%. ORR was 11.9 vs. 24.0% in the second-line group (p=0.19) and 0 vs. 14.3% in the later-line group (p=0.22). Median PFS was 1.7 vs. 4.1 months on second-line (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.35-1.01, p=0.056) and 1.4 vs. 1.8 months on later-line (HR 0.58, 95% CI 0.23-1.46, p=0.25); AEs of any grade were observed in 58.3 vs. 69.7%, respectively. Conclusions The efficacy and safety of the two doses of nivolumab monotherapy were comparable in patients with advanced ESCC.
No takes yet. Share an insight, caveat, or question.
Murashima et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: